Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 101 - Artiva Biotherapeutics

Next Previous
Drug Profile

AB 101 - Artiva Biotherapeutics

Alternative Names: AB-101 - Artiva Biotherapeutics; AlloNK®

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GC Lab Cell
  • Developer Affimed Therapeutics; Artiva Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacements; Natural killer T cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hodgkin's disease; Myositis; Peripheral T-cell lymphoma; Rheumatoid arthritis; Sjogren's syndrome; Systemic scleroderma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Autoimmune disorders; Lupus nephritis; Systemic lupus erythematosus
  • Clinical Phase Unknown Anti-neutrophil cytoplasmic antibody-associated vasculitis; Pemphigus vulgaris
  • Preclinical Multiple myeloma
  • No development reported B-cell lymphoma

Most Recent Events

  • 25 May 2025 Phase-II clinical trials in Myositis (Combination therapy) in USA (Parenteral) (NCT06991114)
  • 25 May 2025 Phase-II clinical trials in Rheumatoid arthritis (Combination therapy) in USA (Parenteral) (NCT06991114)
  • 25 May 2025 Phase-II clinical trials in Sjogren's syndrome (Combination therapy) in USA (Parenteral) (NCT06991114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top